People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. | — | Biotechnology | Growth/Late | $411.8M | $17.5B | 2018 |
DAVID M. BONDERMAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID M. BONDERMAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua A. Kazam | 1 | 10 |
| David M. Tanen | 1 | 8 |
| ROBERT M. ABRAHAM | 1 | 1 |
| OWEN M. WITTE | 1 | 1 |
| TODD M. SISITSKY | 1 | 1 |
| DAVID M. CHANG | 1 | 1 |
| FRANZ M. HUMER | 1 | 1 |
| ARIE M. BELLDEGRUN | 1 | 1 |
| JOHN M. DEYOUNG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.